Expression and function alterations of OAT1 play an essential role in therapeutic efficacy and the toxicity of many drugs, such as for anti-cancer drugs methotrexate, bleomycin, and cisplatin-related toxicity (73–75). The gene discussed is SLC22A6; the disease is cancer.